Inspira Technologies (IINN) announced positive initial results from its collaboration with Ennocure MedTech to develop a novel bio-electronic treatment for preventing bloodstream infections. In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over a 24-hour period. The bio-electronic technology is being designed to address several key challenges associated with traditional IV dressings, including: prevention of bacterial growth through physical rather than chemical means, potential for extended wear time, reducing frequency of dressing changes, applicability to both skin surface and cannula areas and real-time monitoring capabilities.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Poised for Advantage Amid Potential U.S. Tariffs on European Medical Devices
- Inspira Technologies Enhances HYLA Sensor with New Oxygenation Indicator
- Inspira Technologies Enhances INSPIRA ART100 with Advanced Features
- Inspira Technologies announces deployment of first INSPIRA ART100 systems
- Inspira Technologies Appoints Tal Parnes as New Chairman